ClinicalTrials.gov marked primary completion on 2026-05-27 for phase 3 study NCT03383458 of nivolumab in hepatocellular carcinoma. The trial enrolled 545 participants who had undergone curative hepatic resection or ablation and were considered at high risk of recurrence.
Background
The study focused on hepatocellular carcinoma, also listed as liver cancer, in the post-curative setting. Nivolumab is the only intervention named in the record, and the trial compared it with placebo to see whether treatment could improve recurrence-free survival after complete resection or a complete response after local ablation.
Trial design
According to the ClinicalTrials.gov summary, the study was designed to evaluate whether nivolumab would improve recurrence-free survival versus placebo in participants with HCC who were at high risk of recurrence after curative hepatic surgery or ablation. The overall status was listed as ACTIVE_NOT_RECRUITING, and the posted record identified the study as phase 3.
What this means
Primary completion means the main study follow-up milestone has been reached for this large post-curative HCC trial, so the key recurrence-free survival question can now move toward analysis and reporting. Because the record provides no outcome results here, it does not yet show whether nivolumab changed recurrence risk versus placebo in this population.
Source
This information is based on ClinicalTrials.gov study record NCT03383458, with primary completion dated 2026-05-27. The record is available at clinicaltrials.gov.